Unilife Corp. (Nasdaq: UNIS) completed its internal investigation into possible securities violations by former chief executive Alan Shortall and has found no financial loss to the company. With the investigation complete, the company has filed its delayed annual and first quarter financial reports. Shares of the injectable drug delivery system maker leaped $1.18 to close at $2.93.
Unilife completes internal investigation
October 24, 2016 at 17:27 PM EDT
